Breast cancer claims around 6,70,000 lives in a year. As per the data released by the World Health Organisation (WHO) breast cancer was the most common cancer in women in 157 countries out of 185 in 2022. Over 2 million women are diagnosed with breast cancer every year. This necessitates early diagnosis of the deadly disease and finding a drug targeting the cancerous cells.
The US Food and Drug Administration (FDA) has approved Kisqali for early stage breast treatment. The drug, also known as ribociclib, has been approved for use in combination with hormone therapy for early stage breast cancer patients. This will be helpful for those patients who have a concern over the return of cancer.
